Early Returns on Small Molecule Therapeutics for SARS-CoV-2SARS-CoV-2에 대한 저분자 치료제의 조기 수익Article Published on 2021-06-112022-09-11 Journal: ACS Infectious Diseases [Category] SARS, 신약개발, 치료제, [키워드] approach breadth clinical testing Computational approaches COVID-19 pandemic determine effort Extraordinary identify molecule Pandemics Potential treatment potential treatments preparation progression return SARS-CoV-2 SARS-COV-2 infection Scientific community small molecule Therapeutics treat [DOI] 10.1021/acsinfecdis.0c00874 PMC 바로가기 [Article Type] Article
Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancyCOVID-19의 잠재적 치료제로 사용 가능한 약물: 임신 중 알려진 안전성 프로파일은 무엇입니까?Research Article Published on 2021-05-192022-09-10 Journal: PLoS ONE [Category] SARS, 신약개발, 치료제, [키워드] 95%CI Adjusting age angiotensin ARB Azithromycin Birth weight blocker caution Chloroquine clinical trial clinical trials condition confounder confounders congenital malformation COVID-19 Dexamethasone during pregnancy eligible excluded exposure to gestational age gestational period heparin heparins HIV Hydroxychloroquine increased risk indication indications interferon interferons LBW Low birth weight medication medications oseltamivir outcomes Potential treatment potential treatments pregnancies Pregnancy pregnant women Prematurity quantified Result risk safety profile Taking treat treatments for COVID-19 trials unique with COVID-19 women [DOI] 10.1371/journal.pone.0251746 PMC 바로가기 [Article Type] Research Article
Etoricoxib may inhibit cytokine storm to treat COVID-19Etoricoxib는 COVID-19를 치료하기 위해 사이토카인 폭풍을 억제할 수 있습니다Article Published on 2021-05-012022-09-11 Journal: Medical Hypotheses [Category] 신약개발, [키워드] absence arachidonic acid caused conversion COVID-19 Cyclooxygenase Cytokine storm drug Etoricoxib IL-6 inhibit NSAID patients potential treatments present prostaglandin reducing spread of COVID-19 treat Vaccines [DOI] 10.1016/j.mehy.2021.110557 PMC 바로가기 [Article Type] Article
SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibitionSARS-CoV-2 감염은 숙주 세포 대사를 다시 연결하고 잠재적으로 mTORC1 억제에 취약합니다Article Published on 2021-03-252022-09-12 Journal: Nature Communications [Category] SARS, 진단, [키워드] Activation Air-liquid interface Alter block carbon caused cell line cell lines change changes COVID-19 COVID-19 patient COVID-19 patients cultures determine Efficacy epithelial epithelial cell epithelial cells Evidence evidence of expression facilitate feasible Glucose Glutamine host cell host cell metabolism increase inhibitor kidney lung lung ALI cultures lung tissue mechanism Mechanisms of disease metabolism mTORC1 Mucosal immunology oxidative pandemic of COVID-19 patients Potential treatment potential treatments pyruvate reduce reduce viral replication Replication required SARS-CoV-2 SARS-COV-2 infection suppresse susceptible TCA cycle therapy TOR signalling Treatment understanding viral infection viral replication [DOI] 10.1038/s41467-021-22166-4 PMC 바로가기 [Article Type] Article
Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics고 처리량 스크리닝 데이터베이스의 마이닝은 COVID-19 치료제의 잠재적 표적으로서 AP-1 및 자가포식 경로를 나타냅니다Article Published on 2021-03-242022-09-10 Journal: Scientific Reports [Category] SARS, 신약개발, 유전자 메커니즘, 임상, 치료제, [키워드] addition Anti-SARS-CoV-2 Activity Antiviral AP-1 approved approved drug approved drugs autophagy autophagy pathway Candidates caused class coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 therapeutics CPE Cytopathic effect Data mining database drug drug activity drug library effective effort global pandemic High-throughput screening Hope house human clinical trials in vivo mechanism New coronavirus new coronavirus SARS-CoV-2 phenotypic Potential treatment potential treatments profile pursuit reveal SARS-CoV-2 SARS-COV-2 infection signaling pathway significantly target Target identification therapeutic Viral [DOI] 10.1038/s41598-021-86110-8 PMC 바로가기 [Article Type] Article
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical PeculiaritiesReview Published on 2021-02-252022-10-28 Journal: Pharmaceutics [Category] COVID-19, [키워드] administration Antiviral Antiviral effect approved benefit chloroquine/hydroxychloroquine Clinical improvement COVID-19 death dietary supplements drug Drug repurposing drugs effective Efficacy heparin high risk highlight Hydroxychloroquine insight Lopinavir/ritonavir Mortality Older Ozone patients pharmaceutical pharmaceutical formulations pharmacokinetic phosphodiesterase inhibitors potential treatments reduced risk Regulatory Remdesivir reported repurposing Safe safety profile Severe respiratory distress syndrome tested treatments for COVID-19 [DOI] 10.3390/pharmaceutics13030302 PMC 바로가기 [Article Type] Review
Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs누락된 임상 시험 데이터: 잠재적인 COVID-19 약물에 대한 기본 데이터의 증거 격차Research Published on 2021-01-152022-09-10 Journal: Trials [Category] 신약개발, 임상, 치료제, [키워드] adverse events blinded caution checked Clinical findings clinical trial Clinical trial transparency clinical trials ClinicalTrials Concordance conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 treatment disease dosages drug Evidence Favipiravir Google Scholar Hydroxychloroquine Identifier identify in vitro include information lack Lopinavir missing morbidity and mortality pandemic Potential treatment potential treatments regimen registry Repurposed drugs Result Safety information searched Sponsor synthesis Treatment Trial trials [DOI] 10.1186/s13063-021-05024-y PMC 바로가기 [Article Type] Research
PROMISCUOUS 2.0: a resource for drug-repositioningPROMISCOUS 2.0: 약물 재배치용 리소스Article Published on 2021-01-082022-09-11 Journal: Nucleic Acids Research [Category] 신약개발, 치료제, [키워드] approaches approved can be used candidate drug candidate drugs Cheminformatics compounds costly COVID-19 COVID-19 pandemic disease drug drug-target interaction Drug-target interactions effort emerging disease expand identify indication indications information open Patient Potential treatment potential treatments reduce researcher resource Section Side-effect Side-effects significantly similarity small molecule Small molecules time-consuming unique user user experience widespread [DOI] 10.1093/nar/gkaa1061 PMC 바로가기 [Article Type] Article
Creation and maintenance of a table for assessment of evolving evidence for COVID-19-related treatmentsCOVID-19 관련 치료에 대한 진화하는 증거 평가를 위한 테이블 생성 및 유지Review Published on 2021-01-052022-09-11 Journal: American journal of health-system pharmacy : AJHP [Category] 임상, 치료제, [키워드] applied available data clinical trial clinical trials Comment coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 drug treatment COVID-19 pandemic creation develop dosage drug drug information drug treatment Efficacy evaluate Evidence evidence-based practice for inclusion Healthcare professional healthcare professionals information limitation list maintenance pandemic Pandemics Patient patients with COVID-19 point of care Potential Potential treatment potential treatments rationale recommendation regimens resource Society supportive care table therapy Treatment Trial [DOI] 10.1093/ajhp/zxaa334 PMC 바로가기 [Article Type] Review
The Effect of Exogenous Surfactant on Moderate and Severe Stages of COVID-19 Induced ARDS: the Pilot Study of a Clinical TrialOriginal Article Published on 2021-01-012022-10-30 Journal: Iranian Journal of Pharmaceutical Research : IJPR [Category] COVID-19, [키워드] alleviate alveolar cells Analysis ARDS Blood clinical Clinical outcome clinical trial control arm COVID-19 COVID-19 adult patients COVID-19 pandemic COVID-19 patient COVID-19 patients dose Effect Effects Exogenous Face mask form Health ICU induced Inflammatory Intubated lung dysfunction moderate P/F ratio Patient pilot study Potential treatment potential treatments previous study pulmonary involvement severe COVID-19 significantly Stage surfactant treatment arm trials virus with COVID-19 [DOI] 10.22037/ijpr.2021.115390.15347 PMC 바로가기 [Article Type] Original Article